Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 2/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 3/20 | 0.41 |
| ▸ | PLAU | P00749 | 3/20 | 0.41 |
| ▸ | PLAT | P00750 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27817084 | 0.94 | NOS1 (0.48) | NOS1NOS2NOS3TAAR1PNMT | |
| SCHEMBL18885685 | 0.90 | PLG (0.43) | NOS1NOS2NOS3TAAR1PNMT | |
| SCHEMBL3780943 | 0.88 | TAAR1 (0.53) | NOS1NOS2NOS3TAAR1PNMT | |
| SCHEMBL3792838 | 0.86 | TAAR1 (0.54) | TAAR1LOXL2HTR7 | |
| SCHEMBL3786351 | 0.84 | HRH3 (0.58) | NOS1NOS2NOS3TAAR1LOXL2 | |
| SCHEMBL3791745 | 0.83 | LOXL2 (0.60) | NOS1NOS2NOS3TAAR1PNMT | |
| SCHEMBL3727224 | 0.82 | TAAR1 (0.54) | NOS1NOS2NOS3TAAR1PNMT | |
| SCHEMBL18882742 | 0.82 | MAOB (0.46) | NOS1NOS2NOS3TAAR1PLG | |
| SCHEMBL27651141 | 0.79 | NOS1 (0.46) | NOS1NOS2NOS3TAAR1PNMT | |
| SCHEMBL15125637 | 0.79 | TAAR1 (0.63) | NOS1TAAR1KARS1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | NOS1 3102/4885NOS2 2063/4885NOS3 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.